Home/News Feed/Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs. Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, reflecting confidence in its mid-term outlook. Novartis also highlighted a robust pipeline with over 35 potential submission-enabling readouts and 30 high-value assets, including 10 late-stage developments expected to sustain mid-single-digit growth long term. This outlook supports continued innovation and growth despite upcoming patent expirations.
Novartis's optimistic sales growth and pipeline updates come as the stock remains stable on Pluang, trading at USD 159.18 with a slight 0.03% increase as of Nov 19, 2026 13:01 WIB. The company's market cap stands at $299.64 billion, reflecting its significant presence in the health sector. Investors on Pluang typically hold NVS shares for about 85 days, with a dividend yield of 2.98%.